Expertise shared with gynecologic oncology professionals from around the world.
As the extent of surgical debulking increases, with 100,000 women undergoing this surgical evaluation each year, so does the risk of bleeding, venous thromboembolism (VTE), and nosocomial infection.
At the Society of Gynecologic Oncology (SGO) Annual Meeting in Maryland, Dr. Saketh Guntupalli shared results of a prospective, randomized, open-blinded trial comparing oral apixaban to subcutaneous enoxaparin; these results were the planned safety interim analysis including 120 patients undergoing surgical evaluation for gynecologic cancer.
The results, involving two groups of 60 patients each undergoing surgical evaluation for gynecologic cancer, showed that there were no major bleeding events in either group.